Market's view on Futura Medical
Published on April 2024
- APH (Alliance Pharma) is highlighted for its record revenues increase of 6% to £182.7m and a FY24 profit guideline of £50m, alongside strong consumer demand and a 34% increase in free cash flow to £21.1m.
- Concerns are raised about a company with a market capitalisation of £102m having no revenue.
- Issues are noted with the Futura Medical website, including the removal of references to PET500/Epic spray and the vanishing FAQ section.
- There are doubts about the progress of Futura Medical, with past products failing to meet expectations.
- Queries about the significant spend on plant and equipment by a company last financial year and speculation about the timing of the next cash raise.
- Contradictions are pointed out between what Futura claimed in presentations and the reality, particularly regarding sales figures and market share for Eroxon, which reportedly captured only 20% of a small online market of approved ED treatments.